Haruna Muwonge
ID: UNCST-2019-R000128
|
A Randomized, Double-Blinded, Placebo-Controlled, Phase III, Clinical Trial of SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in Adults Aged 18 Years and Above
REFNo: HS2185ES
Safety: To evaluate adverse events from the first dose and the booster dose to Day 28 after the whole-course immunization and serious adverse events from the first dose and the booster dose to at least 12 months after the whole-course immunization,Efficacy: To evaluate the efficacy of the SARS-CoV-2 Vaccine, Inactivated (Vero Cell) for symptomatic and laboratory-confirmed (RT-PCR method) COVID-19 cases caused by different SARS-CoV-2 variants,Immunogenicity: To evaluate the immune persistence of the investigational vaccine,Immunogenicity: To demonstrate the consistency of 3 lots of investigational vaccine in terms of GMT 14 days after the whole-course immunization,Immunogenicity: To evaluate the levels of neutralizing antibody and IgG antibody against SARS-CoV-2 14 days after the whole-course and after the booster immunization,Efficacy: To evaluate the efficacy of the SARS?CoV?2 Vaccine, Inactivated (Vero Cell) against symptomatic and laboratory-confirmed (RT?PCR method) severe COVID-19 disease,Efficacy: To evaluate the efficacy of the SARS?CoV?2 Vaccine, Inactivated (Vero Cell) after at least one dose, 2 doses, and after the booster dose of immunization,To evaluate the efficacy, safety and immunogenicity of the SARS?CoV?2 Vaccine, Inactivated (Vero Cell) in adults aged 18 years and above after a 2-dose schedule, and after booster vaccination,
|
Kayunga, Ntenjeru
Jinja, Nakasero
Mityana, Central Ward
Mubende, Kyaterekera
Gulu, Agwee
Wakiso, Central Ward
Mukono, Ggulu Ward
Kampala, Mulago I
|
Uganda |
2022-04-07 |
2025-04-07 |
5000 |
Adults 18years and above, male and female, all tribes that fulfill the study inclusion criteria |
Institute of Medical Biology Chinese Academy of Medical Sciences |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Miriam Nakalembe
ID: UNCST-2021-R014040
|
Simplified Treatment for Eclampsia Prevention using Magnesium sulfate: A phase III, randomized, open label, active controlled, multicountry, multicentre, non-inferiority trial of simplified magnesium sulfate regimen for eclampsia prophylaxis (The STEP-Mag Trial).
REFNo: HS2076ES
The primary objective of this trial is to evaluate non-inferiority of magnesium sulfate 10g IM administered 12 hourly x 2 doses compared with a standard IV (Zuspan) or IM (Pritchard) magnesium sulfate regimen1 in the prevention of maternal eclamptic seizure.
The secondary objective of this trial is to evaluate superiority of magnesium sulfate 10g IM administered 12 hourly x 2 doses compared with a standard IV (Zuspan) or IM (Pritchard) magnesium sulfate regimen in the proportion of women experiencing adverse events indicative of magnesium toxicity.
|
Kampala, Kawempe
|
Uganda |
2022-04-02 |
2025-04-02 |
1500 Uganda |
The target trial population are women admitted to participating hospitals with pre-eclampsia during pregnancy, labour or within 24 hours of childbirth, whether it involves a single or multiple gestation.
|
World Health Organisation |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Thereza Piloya Were
ID: UNCST-2019-R000491
|
Diabetes in African Youth: Improving Glucose Time-In-Range (DAY Time) Randomized Clinical Trial.
REFNo: HS2129ES
Primary Study Objectives
1. To determine if patient ability to continuously observe plasma glucose levels for 6 months using a flash intermittently scanned CGM improves glucose TIR compared to baseline. The change in glucose TIR while wearing the unblinded CGM will be compared to change in TIR in patients performing 3x/day SMBG (wearing a blinded CGM for endpoint measurement).
2. To perform a cost analysis on flash glucose monitoring compared to 3x/day SMBG, to determine whether this technology is cost effective in the setting of a low-resource nation.
Secondary Objectives: To assess the change-from-baseline impact of unblinded CGM on:
1. Percent time-in-range at 12 months
2. Percent time with glucose 180-250, >250, <70, and <54 mg/dl at 6 and 12 months
3. HbA1c at 6 and 12 months
4. Patient satisfaction and quality of life at 6 and 12 months
5. Glucose variability (coefficient of variation, CV) at 6 and 12 months
|
Kampala, Mulago
Kampala, Nsambya
|
Uganda |
2022-04-01 |
2025-04-01 |
180 randomized in 2 groups : - 90 per group |
Inclusion Criteria
? Children and youth in Uganda, age 4-26 years at baseline
? T1D of at least 12 months duration at baseline
? Receiving insulin therapy
? Access to a cell phone (nearly ubiquitous in Uganda, even in remote areas)
? Participant/pare |
United States of America, National Institute of Health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Pontiano Kaleebu
ID: UNCST-2020-R019901
|
Performance evaluation of the CheckNOW™ HIV Self-Test study
REFNo: HS2170ES
1. To evaluate the performance (Sensitivity and specificity) of the CheckNOW™ HIV SELF TEST when compared to the Genscreen ULTRA HIV1/2 Ag/Ab EIA followed by the Murex diasorin HIV1/2 Ag/Ab combination (reference testing) in the laboratory and the national testing algorithm.
2. To describe the clinical performance (sensitivity and specificity) of the CheckNOW™ HIV SELF TEST, as obtained by the professional users, when compared to the reference testing and the national testing algorithm.
3. To describe the clinical performance (sensitivity and specificity) of the CheckNOW™ HIV SELF TEST, as obtained by the lay users, when compared to the reference testing and the national testing algorithm.
4. To assess the accuracy of the lay user interpretation of the HIVST result. This will be compared with the interpretation by the RA.
5. To assess the usability of the CheckNOW™ HIV SELF TEST. The usability of the test will be evaluated by questionnaires completed by the study staff observers and by the lay users.
|
Kampala, Kampala
Kalungu, Kalungu
Kayunga, Kayunga
Mukono, Mukono
|
Uganda |
2022-04-01 |
2025-04-01 |
1000 |
Adults aged 18 years and above who are willing to have an HIV test. |
- Abott Diagnostics |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Fred Ssewamala
ID: UNCST-2020-R014060
|
Suubi4Stronger Families: Addressing Child Behavioral Health by Strengthening
Financial Stability and Parenting among Families in Uganda
REFNo: SS1205ES
The study examines the mechanisms by which economic empowerment (EE) and family strengthening (FS) interventions targeting social, familial and context-specific drivers affect childhood behavioral health.
Specific aims of the study are:
Aim 1: Examine the impact of EE only, MFG-based FS only, and combined EE+MFG-based FS on children’s DBD symptoms and behavioral functioning.
Aim 2: Test the influence of EE only, MFG-based FS only, and combined EE+MFG-based FS on family financial stability (e.g., food and housing stability, material assets, savings), parenting and protective family
processes (e.g., family organization, caregiver/child interaction, cohesion, support) and perceptions related to
help seeking (e.g., stigma) on CBH and functioning; and assess whether these change mechanism mediate intervention effects on DBD symptoms and behavioral functioning, and explore moderation by context specific moderators of intervention effects.
Aim 3: Qualitatively examine participants’ experiences with each intervention arm.
|
Masaka, Kimaanya
Rakai, Kakuuto
Kyotera, Kyotera TC
Lwengo, Lwengo
Kalungu, Bukulula
|
Uganda |
2022-03-30 |
2025-03-30 |
900 |
A total of 900 primary-school-going children (ages 10-14 at enrollment) in upper primary (the last 3 year of
primary school: P5-P7), both male and female will be enrolled and followed for three school-academic terms(12 months). To avoid stigma that surro |
National Institute of Mental Health (NIMH) |
Social Science and Humanities |
Clinical Trial |
Non-degree Award |
|
SIMON ARUNGA
ID: UNCST-2021-R013498
|
Cluster randomised controlled trial of a complex intervention package to reduce blindness from severe microbial keratitis in Uganda.
REFNo: HS1814ES
To determine if a complex intervention package delivered at the Primary Health Centres (PHCs) including early recognition, prompt chlorhexidine 0.2% treatment and rapid referral can result in reduced rates of blindness from severe MK at three months
|
Ntungamo, All parishes
Isingiro, All parishes
|
Uganda |
2022-03-21 |
2025-03-21 |
Participants Individuals with corneal abrasions and corneal infection (microbial keratitis) presenting at the cluster primary health centres in these two districts in South Western Uganda will be elig |
All individuals aged 18 and above, of all sexes in the two districts |
London School of Hygiene and Tropical Medicine |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Johanna Blomgren
ID: UNCST-2021-R012309
|
MIDWIZE - Strengthening midwives to implement and sustain quality improvements to optimise maternity care: A longitudinal observational study in Uganda
REFNo: HS1885ES
This PhD project aims to explore how midwives can take the lead in implementing or enhancing QI components within maternal health care in Uganda.
The overall goal of this project is to improve the health of women and newborns. The way to achieve this is through enhancing the quality of care by capacitating midwives.
Sub-study 1 - Co-creating and developing the intervention and the implementation
Specific objectives: To explore multisectoral stakeholders' perspectives and ideas on how to strengthen midwives' capacity to implement QI components.
To explore which QI components the midwives will implement or enhance.
Sub-study 2 - Implementation and evaluating the sustainability of the implementation
Specific objectives:
-To measure the uptake of evidence-based QI components when midwives lead, organise and provide enhanced intra- and postpartum care.
-To measure the long-term sustainability of the midwives' QI projects.
Sub-study 3 – Process evaluation
Specific objective: To evaluate the process of strengthening midwives' capacity to implement QIs in maternal care.
|
Kampala,
|
Sweden |
2022-03-21 |
2025-03-21 |
668 |
Study 1
Midwives at Naguru hospital, women and their relatives, other professionals and managers, multisectoral stakeholders (professional association, education, policymakers)
Study 2
Pregnant women above 18 years in the uptake area. However, dependin |
Karolinska Institutet |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
.png)
|
Pontiano Kaleebu
ID: UNCST-2021-R013577
|
A Randomized, Observer-Blind, Phase 2 Clinical Trial of COVAC-2 in Generally Healthy Adults
REFNo: HS2124ES
Primary Objective:
• To evaluate the safety and tolerability of the COVAC-2 vaccine (25 ?g dosing of S1 antigen) in generally healthy adults ages 18+.
Secondary Objectives:
• To determine spike-binding and pseudovirus neutralizing antibody responses against the Wuhan strain of SARS-CoV-2 induced by COVAC-2; and
• To determine a cellular immune response induced by COVAC-2.
Exploratory Objectives:
• To determine Receptor-Binding Domain (RBD)-binding antibody responses induced by COVAC-2; and
• To determine the neutralizing antibody response induced by COVAC-2 against one or more Variant(s) of Concern (VOC) and/or Variant(s) of Interest (VOI).
|
Wakiso, NOT APPLICABLE
Mbarara, NOT APPLICABLE
Masaka, NOT APPLICABLE
|
Uganda |
2022-03-21 |
2025-03-21 |
300 |
The target population for this Phase 2 study is generally healthy adults of diverse gender ? 18 years of age. The target indication for the candidate COVAC-2 vaccine is adults because they are a population that experiences significant age-related COVID-19 |
The study is funded by the Government of Canada through the University of Saskatchewan’s Vaccine and Infectious Disease Organization (VIDO). |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Pauline Byakika-Kibwika
ID: UNCST-2019-R001206
|
Exposure-Response Evaluation of IV Artesunate in Children with Severe Malaria
REFNo: HS2027ES
Primary:
• To determine the relationship between dihydroartemisinin (DHA) exposures following intravenous dosing and markers of physiologic dysfunction associated with severe malaria
Secondary:
• To determine the relationship between DHA exposures and time to hospital discharge
• To determine the relationship between DHA exposures and parasite clearance associated with treatment of severe malaria.
Exploratory:
• To determine the relationship between DHA exposures and neurodevelopmental outcomes associated with treatment of severe malaria outcomes and explore predictors that may affect this relationship
• To evaluate the role of parasite clearance as a mediator of the relationship between DHA exposures and markers of physiologic dysfunction associated with severe malaria
• To develop a score comprised of markers of physiologic dysfunction and describe its relationship to clinical outcomes
• To assess P. falciparum infections for artemisinin resistance
|
Tororo, central division
|
Uganda |
2022-03-14 |
2025-03-14 |
100 |
Children with severe malaria who are 6 months to 14 years of age living in or near Tororo District, Uganda |
VTEU Contract HHSN2722013000221 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Joseph Ngonzi
ID: UNCST-2019-R001579
|
Automated visual evaluation and geospatial mapping for cervical cancer screening optimization in sub-Saharan Africa (AVE-Map)
REFNo: HS2069ES
3. To use AVE and geospatial analysis to scale up cervical cancer screening in Uganda ,2. To determine access to cervical cancer screening and referral pathways in Uganda ,1. To validate and expand use of AVE for cervical cancer screening in SSA ,We aim to leverage and develop data science expertise at our sites to first optimize and then combine AVE-based screening by health workers at peripheral health facilities with geospatial-analysis and needs-driven assessment to inform scale-up of cervical cancer screening in Uganda ,
|
,
Mbarara, Kakoba
|
Uganda |
2022-02-28 |
2025-02-28 |
2000 |
Females aged 25 years and above |
NATIONAL INSTITUTE OF HEALTH |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Musa Sekikubo
ID: UNCST-2021-R014010
|
A placebo controlled clinical trial investigating the safety and immunogenicity of GBS6 in pregnant women with and without human immunodeficiency virus (HIV) infection and their infants
REFNo: HS1991ES
1. To describe the safety and tolerability of GBS6 when administered at ? 27 0/7 to ? 35 6/7 weeks’ gestation to pregnant women, with and without HIV, aged ? 18 to ? 40 years of age and their infants..
2. To assess the safety of GBS6 in infants born to HIV positive and negative women who were vaccinated during pregnancy.
|
Kampala, Kawempe
Kampala, Kisenyi
|
Uganda |
2022-02-11 |
2025-02-11 |
300 |
pregnant women aged 18 to 40 years at gestation age of ? 27 0/7 to ?35 6/7 weeks. |
St George’s, University of London Cranmer Terrace SW17 0RE |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Aisha Nanyiti
ID: UNCST-2021-R013489
|
A Randomized Control Trial (RCT) on the Adoption of Liquefied Petroleum Gas (LPG) Cooking Technology among Fast Food (Chapati) Vendors in Uganda
REFNo: SS1017ES
This study seeks to establish the impact of hire purchase schemes and health and safety information on adoption of LPG cookstoves by chapati vendors.
This study will achieve the following specific objectives:
1) The impact of learning from LPG use in grace period before purchase armotisation on adoption of LPG cookstoves by chapati vendors for their businesses and households.
2) The impact of hire purchase on adoption of LPG cookstoves by chapati vendors for their businesses and households.
3) The impact of information on safety and health benefits of LPG on adoption of LPG cookstoves by chapati vendors for their businesses and households.
4) The impact of peer learning from other vendors using LPG cookstoves on adoption of LPG cookstoves by chapati vendors for their businesses and households.
|
Kampala,
|
Uganda |
2022-02-10 |
2025-02-10 |
210 |
chapatti vendors; they are mainly males of age range in 18-45 years from all districts of Uganda. |
Environment for Development Initiative |
Social Science and Humanities |
Clinical Trial |
Non-degree Award |
|
Robert Kalyesubula
ID:
|
Effectiveness of a community health worker delivered care intervention for hypertension control in Uganda: a stepped wedge, cluster randomized control trial.
REFNo: HS1917ES
To assess the effectiveness of a CHW-delivered intervention for hypertension control in Uganda.,
|
Nakaseke, Kigegge, Bulwadda, Mifunya, Kyamutakasa, Kasambya, Kasagga, North Ward. East Ward. Namilali, Kivule Central Ward
|
Uganda |
2022-02-10 |
2025-02-10 |
900 |
Hypertensive patients, 18 years and above, attending Nakaseke hospital or Life Care NCD clinics, and residing either in Nakaseke town council, Nakaseke Subcounty or Kasangombe. |
Else Kroner Fresenius Stiftung |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Fred Ssewamala
ID: UNCST-2020-R014060
|
M-Suubi: A Multi-Level Integrated Intervention to Reduce the Impact of HIV Stigma on HIV Treatment Outcomes among Adolescents Living with HIV in Uganda
REFNo: SS1166ES
Aim 1: Examine the impact of M-Suubi on HIV viral suppression (primary outcome); and adherence to HIV treatment (keeping appointments, pharmacy refills, pill counts), and retention in care (secondary outcome).
Aim 2: Examine the effect of M-Suubi on Stigma (internalized anticipated, and enacted), with secondary analyses to explore hypothesized mechanisms of change (e.g. depression) and intervention mediation.
Aim 3: Assess the cost and cost-effectiveness of each intervention condition.
Aim 4: Qualitatively examine: a) participants’ experiences with HIV stigma, HIV treatment adherence, and the intervention; and 2) educators’ attitudes towards ALHIV and experiences with GED-HIVSR, and program/policy implementation post-training.
Aim 5: Conduct formative work (focus group discussions) to understand the needs of depressed ALHIV.
|
Masaka, Kimaanya
Kalungu, Bukulula
Rakai, Kakuuto TC
Lyantonde, Lyantonde TC
Bukomansimbi, Butenga
Lwengo, Lwengo
|
Uganda |
2022-02-04 |
2025-02-04 |
840 dyads |
The target populations for this study will be ALHIV, their caregivers (N=840 child-caregiver dyads), and administrators attending 42 boarding schools in the greater Masaka region. Participants will be included in the study if they meet the following inclu |
National Institute of Mental Health (NIMH) |
Social Science and Humanities |
Clinical Trial |
Non-degree Award |
|
Emmy Okello
ID: UNCST-2020-R009792
|
Remote Ischaemic Conditioning in STEMI patients in sub-Saharan AFRICA: The RIC-AFRICA trial
REFNo: HS1865ES
RIC will reduce the rates of all-cause death and early post-myocardial heart failure by approximately 25% when compared to sham control.,The RIC-AFRICA trial will investigate the effect of RIC in STEMI patients on the rates of all-cause death and early post-MI heart failure (pre-discharge HF and hospitalisation for HF at 30 days post-MI,) when compared to sham control,
|
,
Kampala, MULAGO
|
Uganda |
2022-02-01 |
2025-02-01 |
1500 |
Participants will be recruited from the Uganda Heart Institute and other nearby
state and private hospitals with STEMI care with in Uganda and other
collaborating sites in Sub-Saharan countries
|
Mancherje-Potash Foundation, USA |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Jackson Mukonzo
ID: UNCST-2021-R013916
|
Safety and Efficacy of COVIDEX™ Therapy in Management of adult Covid-19 Patients in Uganda: A randomized double-blind placebo controlled adaptive phase 2 B clinical trial.
REFNo: HS2041ES
3. To determine the plasma concentration of berberine in COVID-19 patients receiving COVIDEX. ,2. To determine the efficacy of COVIDEXTm for treatment of COVID-19 among adults in Uganda.,To determine the efficacy of COVIDEXTm for treatment of COVID-19 among adults in Uganda.,To validate the safety and determine the efficacy of COVIDEXTm therapy for treatment of COVID-19 in adult Ugandans. ,
|
Mbarara, kakoba
Kampala, mulago 1
|
Uganda |
2022-01-25 |
2025-01-25 |
584 |
Participants who are categorized as mild score 2 (limitation of activities), moderately ill COVID-19 patients score 3 (Hospitalized with no oxygen therapy), score 4(Hospitalized with oxygen by mask or nasal prongs) and hospitalized severe disease score 5 |
JENA HERBALS LTD, MINISTRY OF HEALTH UGANDA |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Susanne Guidetti Gittel Eleonora
ID: UNCST-2021-R012422
|
Participation in everyday life - A randomized controlled trial of
mobile phone-supported and family-centred rehabilitation after
stroke in Uganda
REFNo: HS1528ES
General objective (Overall aim)
To implement and evaluate the effects a mobile phone supported and family-centred rehabilitation intervention F@ce 2.0 aiming to enable performance in daily activities and participation in everyday life among persons who have had a stroke and their family members both in urban (Kampala and its surroundings) and rural (Greater Masaka) areas.
Specific objectives
• To describe the perceived impact of stroke and perceived participation in everyday life in a sample of people with stroke in rural Uganda. (Study 1)
• To evaluate the effects of F@ce in comparison with ordinary rehabilitation among persons with stroke in urban and rural Uganda regarding a) self-efficacy b) perceived performance and participation in everyday activities c) independence in ADL, d) healthcare utilization and e)their families´ perceived participation in everyday activities.(Study 2)
• To explore and describe the experiences of people with stroke and family members of participating in the F@ce (Study 3)
• To evaluate the implementation process of F@ce and to gain knowledge on the mechanisms of impact as well as the contextual factors that might influence the implementation process and its outcome. (Study 4)
• To determine the cost of delivering the F@ce intervention in comparison with the usual rehabilitation (Study 5)
|
Kampala,
Masaka,
Iganga,
|
Sweden |
2022-01-19 |
2025-01-19 |
174 |
The sample size will accommodate for an attrition rate of 10%, based on our pilot study in Uganda, therefore will require the inclusion of a total of 174 participants with stroke, 15 health professionals and 15 caregivers (family members). The study will |
The Swedish Research Council |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Maria NAKACHWA
ID:
|
Mobile Telephone Communication and Utilization of Antenatal Care Services During Pregnancy. A Case Study of Kyotera and Rakai Districts- Uganda
REFNo: HS1957ES
d. To develop a model for the prediction of ANC uptake when mobile telephone communication is used.,c. To evaluate effects of patient factors in the utilization of antenatal care services among expectant mothers in Kyotera and Rakai Districts , Uganda.,b. To assess patient factors influencing mobile telephone communication among expectant mothers in Kyotera and Rakai Districts, Uganda.,a. To examine effects of mobile telephone communication on the utilization of antenatal care services among expectant mothers in Kyotera and Rakai Districts, Uganda.,
|
Rakai, Kitente
|
Uganda |
2022-01-12 |
2025-01-12 |
2214 |
THE STUDY POPULATION CONSTITUTES OF EXPECTANT MOTHERS AGED 15 TO 49 YEARS RESIDING IN KYOTERA AND RAKAI DISTRICTS FROM ALL THE TRIBES IN THESE COMMUNITIES. |
SELF SPONDORED |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
David Lubogo
ID: UNCST-2020-R014473
|
Metabolic Syndrome among Females of Reproductive age in Wakiso district, Central Uganda: Risk factors and Effectiveness of a Community based Nutrition Education Intervention
REFNo: HS1281ES
General objective: To investigate the prevalence of, and factors associated with metabolic syndrome (MetS) and evaluate the effect of a community based nutrition education intervention among females of reproductive age with MetS in Wakiso district, Central Uganda in order to contribute information for the design of interventions for MetS.
Specific objectives
1. To determine the prevalence of, and factors associated with Metabolic Syndrome.
2. To determine optimal WC cut off points for MetS.
3. To determine the effectiveness of a 12 -week community-based nutrition education and counseling intervention for metabolic syndrome on selected cardiovascular outcomes (BP), biochemical outcomes (HDL, TGS, blood sugar), anthropometric measures (WC, weight), behavioral outcomes (dietary intake, physical activity), and on knowledge as an outcome.
4. To explore the female and health care provider perceptions/perspectives towards the nutrition promotion intervention on MetS among female of reproductive age in South Central Uganda.
|
Wakiso,
Wakiso,
|
Uganda |
2021-12-28 |
2024-12-28 |
840 |
Females aged 15- 49 years in Wakiso district. |
Strengthening Education and Training Capacity in Sexual and Reproductive Health and Rights in Uganda (SET-SRHR) and the Government of Uganda |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
JIM ARINAITWE
ID: UNCST-2021-R012572
|
Quit4Life: Adapting and Evaluating a Phone-Based Tobacco Uses Cessation Program for People Living with HIV in Uganda and Zambia.
REFNo: HS1762ES
The goal of the study is to adapt and evaluate the efficacy of a phone-based tobacco cessation intervention for PLWH in Uganda and Zambia in five years. The primary objective of the study is to promote smoking cessation among HIV infected persons. Specifically, 1) adapt a standard short message service (SMS) for tobacco cessation program, 2) Nicotine Replacement Therapy, 3) compare the efficacy of our SMS-based program tailored to meet the needs of PLWH (Quit4Life+) to the current standard of care.
|
Arua, Adumi HCIV, Omugo HCIV and River Oli HCIV
Moroto, Loputuk HCIII, Nadunget HCIII and Tapac HCIII
|
Uganda |
2021-12-28 |
2024-12-28 |
Total Sample size is 800 with 400 from Uganda and 400 from Zambia |
The study will include males and females of consenting age attending HIV services at Health III, IV, District/Regional Referral Hospitals |
National Institute of Health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|
